Hansoh Pharma's innovative drugs added to China's 2025 NRDL

Hansoh Pharmaceutical Group has announced the successful addition of two new indications for its innovative drug, Ameile, to the 2025 National Reimbursement Drug List (NRDL). These new indications, approved in March and April 2025, cover the treatment of adult patients with stage II to IIIB non-small cell lung cancer (NSCLC) with specific EGFR mutations, and locally advanced, unresectable (stage III) NSCLC that has not progressed after chemoradiotherapy, also with specific EGFR mutations.

Additionally, all indications for the innovative drugs Saint Luolai (Pegmolesatide Injection) and Hengmu (Tenofovir Amibufenamide Tablets) have been renewed in the 2025 NRDL. Saint Luolai treats anemia in chronic kidney disease for adult patients both on and off dialysis, while Hengmu is renewed for adult patients with chronic hepatitis B.

The 2025 NRDL will officially take effect on January 1, 2026. The Group also noted that several other innovative drugs, including Hansoh Xinfu, Fulaimei, Xinyue, and existing Ameile indications for NSCLC, remain within their current NRDL agreement period until December 31, 2026. Mailingda has also been included in category B of the general NRDL list.